Company intelligence / Profile preview

Chitogel

Lower Hutt, Wellington Region, New Zealandchitogel.com ↗

Ownership: Private
Development stage: Other

Overview

Chitogel’s hydrogel is FDA-approved for use as a post-operative nasal dressing following endoscopic sinus surgery. Clinical evidence, including over 18 published studies, supports its efficacy in reducing bleeding, scarring, infection, and adhesions while improving patient comfort and wound healing outcomes. The product is commercially available in the US, Australia, New Zealand, UK, and Ireland. Human testing for spinal use has begun.

Therapeutic areas: PulmonologyOther
Modalities: Hydrogel-based drug delivery therapyDevice (post-operative nasal dressing)
Industry: Consumable Medical Devices

Partnerships

Chitogel has signed a heads of agreement with an unnamed major US pharmaceutical multinational for distribution of its ENT gel in the United StatesDP Medical is an exclusive distributor for the UK/Ireland market

Beyond the preview

Go deeper on Chitogel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chitogel.

Explore the full profile